scholarly journals Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapies

2020 ◽  
Vol 10 (8) ◽  
Author(s):  
Cheng Zhang ◽  
Zuhua Chen ◽  
Xiaoyi Chong ◽  
Yang Chen ◽  
Zhenghang Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Targeted Therapies ◽  
Clinical Implications

scholarly journals New drug developments in metastatic gastric cancer

2018 ◽  
Vol 11 ◽  
pp. 175628481880807 ◽  
Author(s):  
Aaron C. Tan ◽  
David L. Chan ◽  
Wasek Faisal ◽  
Nick Pavlakis
Keyword(s):  
Gastric Cancer ◽  
Clinical Trials ◽  
Targeted Therapies ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Treatment Options ◽  
Predictive Biomarkers ◽  
Metastatic Gastric Cancer ◽  
New Era

Metastatic gastric cancer is associated with a poor prognosis and novel treatment options are desperately needed. The development of targeted therapies heralded a new era for the management of metastatic gastric cancer, however results from clinical trials of numerous targeted agents have been mixed. The advent of immune checkpoint inhibitors has yielded similar promise and results from early trials are encouraging. This review provides an overview of the systemic treatment options evaluated in metastatic gastric cancer, with a focus on recent evidence from clinical trials for targeted therapies and immune checkpoint inhibitors. The failure to identify appropriate predictive biomarkers has hampered the success of many targeted therapies in gastric cancer, and a deeper understanding of specific molecular subtypes and genomic alterations may allow for more precision in the application of novel therapies. Identifying appropriate biomarkers for patient selection is essential for future clinical trials, for the most effective use of novel agents and in combination approaches to account for growing complexity of treatment options.

scholarly journals Novel CD9-targeted therapies in gastric cancer

2015 ◽  
Vol 21 (11) ◽  
pp. 3206-3213 ◽  
Author(s):  
Yoko Murayama ◽  
Kenji Oritani ◽  
Shusaku Tsutsui
Keyword(s):  
Gastric Cancer ◽  
Targeted Therapies

scholarly journals CircRNAs in gastric cancer: current research and potential clinical implications

FEBS Letters ◽  
2021 ◽  
Author(s):  
Yixun Lu ◽  
Kai Li ◽  
Yunhe Gao ◽  
Wenquan Liang ◽  
Xinxin Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Clinical Implications

Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 11036-11036
Author(s):  
Tariqa Ackbarali ◽  
Wendy Turell ◽  
Elizabeth L. del Nido ◽  
Adam Brufsky ◽  
Stephen V. Liu
Keyword(s):  
Breast Cancer ◽  
Gastric Cancer ◽  
Clinical Practice ◽  
Patient Experience ◽  
Targeted Therapies ◽  
Her2 Breast Cancer ◽  
Treatment Plans ◽  
Tumor Types ◽  
Behavioral Impact

11036 Background: Improved understanding of the interactions between HER2 and HER3, the heterogeneity of HER-expressing disease, and mechanisms of resistance to anti-HER2 therapy has led to increasing number of treatment options to address clinical needs. Tumor types of interest, impacted by HER2/HER3 expression and pathophysiology were breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, and colorectal cancer (CRC). Increasing competency in these areas is deemed critical to clinician’s ability to individualize treatment plans and improve patient outcomes. Methods: A 2-hour CME activity was broadcast live-online in September 2020 and remains on-demand through September 2021 at OMedLive.com. The educational initiative was divided into one hour addressing HER2 and HER3, testing guidelines, resistance mechanisms and emerging data elucidating recent and ongoing clinical trials across NSCLC, gastric cancer, and CRC. The second hour focused on individualizing metastatic HER2+ breast cancer, HER2-low breast cancer as an emerging subtype, and management of side effects. Knowledge and competence questions were administered pre-, immediate post-, and 2 mos. post-activity. Behavioral impact questions were also asked at follow-up. Data from these questions were analyzed to determine engagement and clinical impact. Results: To date, 448 clinicians participated in the activity. Across the seven CME test questions, improvements in knowledge and competence were observed in the clinical applications of HER2-directed agents and HER3 antibody drug conjugates (ADCs), first-line standard of care for HER2+ breast cancer, and adverse event management for HER2 ADCs. At 2-mos. follow-up, 67% reported improved behavioral impact on both clinical practice and patient experience and outcomes. Clinicians provided specific write-in examples of these changes, noting improved patient-reported outcomes, improved treatment adherence, improved competence developing treatment plans, and increased understanding of HER2/HER3 pathophysiology. Updated and expanded results will be shared. Conclusions: The activity was successful in improving clinician understanding of the relationship between HER2/HER3, pathophysiology across tumor types, and applications of emerging targeted therapies. Open-ended responses to behavioral impact questions illustrated clear improvements in clinician-reported patient experience and outcomes, clinical practice management, and knowledge of emerging HER2/HER3 therapies and their uses across multiple solid tumors.

Growth effect of gastrin on gastric cancer and its clinical implications for gastric cancer surgery

2005 ◽  
Author(s):  
Hyeon Lee ◽  
Hyuk-Joon Lee ◽  
Keun Hur ◽  
Hye Lee ◽  
Woo Kim ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Cancer Surgery ◽  
Growth Effect ◽  
Clinical Implications ◽  
Gastric Cancer Surgery

Targeted Therapies in Metastatic Gastric Cancer: Challenges and Perspectives

2018 ◽  
Vol 07 (02) ◽  
Author(s):  
Ismail Essadi ◽  
Khalid Sair ◽  
Issam Lalya ◽  
Elomrani Abderrahim ◽  
Mouna Khouchani ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Targeted Therapies ◽  
Metastatic Gastric Cancer
Sign in / Sign up

Export Citation Format

Share Document